VYNE Therapeutics Inc. 8-K

What Happened

• VYNE Therapeutics filed a Form 8-K reporting results of a special meeting held July 16, 2026 (record date June 5, 2026) where stockholders voted to approve multiple merger-related proposals under a Merger Agreement with Yarrow Bioscience, Inc. There were 33,385,055 shares outstanding and 25,949,357 shares were present or represented by proxy (quorum).
• Major approvals included: (1) issuance of VYNE common stock to Yarrow (a proposed issuance that would exceed 20% of outstanding shares and cause a change of control under Nasdaq rules); (2) an amendment authorizing a reverse stock split (ratio to be set between 1-for-10 and 1-for-70); (3) increasing authorized common shares from 150,000,000 to 300,000,000; (4) adoption of Yarrow’s 2026 Stock Incentive Plan and 2026 Employee Stock Purchase Plan; and (5) ratification of Baker Tilly US, LLP as independent auditor. Sharon Barbari was elected as a Class II director.

Key Details

• Meeting & record dates: Special Meeting July 16, 2026; record date June 5, 2026. Outstanding shares: 33,385,055; shares represented: 25,949,357.
• Proposal 1 (issuance to Yarrow): For 15,915,017; Against 137,159; Abstain 7,840; Broker non-votes 9,889,341. Approved.
• Proposal 2 (reverse split authorization): For 25,389,760; Against 550,694; Abstain 8,903. Approved. Board to set split ratio (1-for-10 to 1-for-70) and Yarrow must agree.
• Proposal 3 (increase authorized shares): For 23,921,348; Against 2,013,526; Abstain 14,483. Approved.
• Other outcomes: Stock plans approved (Prop 4 & 5); Baker Tilly ratified (Prop 7: For 25,838,022); advisory votes on merger-related executive compensation (Props 8 & 9) passed. Sharon Barbari elected as Class II director (Prop 6).

Why It Matters

• These votes clear key stockholder approvals needed to proceed with the Merger Agreement with Yarrow. Approval of the issuance to Yarrow is material because it exceeds Nasdaq’s 20% threshold and constitutes a change of control under Nasdaq rules.
• The reverse split authorization and increase in authorized shares give VYNE flexibility to adjust share count and issue shares for the merger, which can affect existing holders (potential dilution or change in float) depending on the final split ratio and post-merger issuance. If the Merger is completed, the composition of VYNE’s board will be reconstituted per the Merger Agreement.
• Investors should note the company filed this 8-K to report votes only; any securities offers related to the transaction would require a prospectus or an applicable exemption.